A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70
Study Details
Study Description
Brief Summary
In this study we propose to determine outcomes of patients age 70 or older treated with radiation over 2 weeks given with temozolomide 75 mg/m2 daily during radiotherapy and as a post radiation treatment of 150 mg/m2 - 200 mg /m2 for 6 cycles or until the disease progresses.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Hypofractionated radiotherapy and temozolomide All subjects will receive treatment as is a single arm study. Two weeks of combined hypofractionated radiotherapy with concurrent temozolomide followed by up to 6 cycles of adjuvant temozolomide treatment. |
Radiation: Hypofractionated radiotherapy
Treatment of 3.4 Gy will be given daily 5 days per week over 2 weeks.
Drug: Temozolomide
During concomitant phase Temozolomide will be administered orally at 75 mg/m2 for 2 weeks concomitant with radiotherapy. During the adjuvant phase Temozolomide will be administered orally at 150 mg/m2 on days 1 through day 5 of each 28 day cycle for a maximum of 6 cycles.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of patients who stop treatment due to CTCAE grade 3 or above toxicities [4 weeks after radiation therapy - month 6]
If < 4 out of 10 patients in the initial analysis stop treatment due to toxicity it can proceed to phase II.
Secondary Outcome Measures
- Overall survival [from study enrollment to date of death or up to approximately 5 years]
- Quality of Life [7 months after enrollment]
Quality of life will be measured by Fact-BR assessment.
- The number of patients to complete RT+TMZ and a minimum of 3 of the 6 planned cycles of adjuvant chemotherapy [7 months after enrollment]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participants must have histologically confirmed glioblastoma/gliosarcoma.
-
Tumor o6-methylguanine-DNA-methyltransferase promoter methylation status must be determined
-
Participants must not have had any prior therapy for glioblastoma multiforme including radiation or chemotherapy.
-
Participants must be > 70 years of age.
-
Participants must have life expectancy greater than 6 months.
-
Karnofsky performance status > 60 (ECOG < 2).
-
Patients must have normal organ and marrow function
-
Leukocytes > 3,000/microliter
-
Absolute neutrophil count > 1,500/microliter
-
Platelets > 100,000/microliter
-
Total bilirubin within normal institutional limits 12
-
aspartate aminotransferase test(SGOT)/alanine aminotransferase test(SGPT) < 2.5 X institutional upper limit of normal
-
Creatinine within normal institutional limits or creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels about institutional normal
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
-
Participants may not be receiving any other study agents.
-
Participants may not have had chemotherapy wafer placement at surgery.
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide.
-
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
-
Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
-
HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with temozolomide. In addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | James Graham Brown Cancer Center | Louisville | Kentucky | United States | 40202 |
Sponsors and Collaborators
- University of Louisville
- James Graham Brown Cancer Center
Investigators
- Principal Investigator: Shiao Woo, MD, James Graham Brown Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BCC-NEU-13 GB70